# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Cormedix (NASDAQ:CRMD) with a Buy rating and announces Pri...
RBC Capital analyst Gregory Renza reiterates Cormedix (NASDAQ:CRMD) with a Outperform and maintains $9 price target.
Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:CRMD) with a Buy and maintains $10 price target.
Truist Securities analyst Joon Lee maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $14 to $12.
Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:CRMD) with a Buy and maintains $10 price target.